Review Article
Ginsenoside Rg3 (Shenyi Capsule) Combined with Chemotherapy for Digestive System Cancer in China: A Meta-Analysis and Systematic Review
Table 4
Sensitivity analysis via excluding the under- or overestimated trials.
| Indicators | Trials | OR (95% CI) | I2 | Excluded studies [Reference] | Trials | OR (95% CI) | I2 |
| ORR (CRC) | 3 | 2.43[1.06, 5.60] | 57% | Zeng et al. CRC [23] | 2 | 3.39[1.21, 9.54] | 57% | DCR (CRC) | 3 | 2.74[0.85, 8.79] | 62% | Zeng et al. CRC [23] | 2 | 4.85[2.04, 11.53] | 0% | SR (1-year) | 6 | 2.33[1.24, 4.37] | 53% | Zhou et al. GC [18] | 5 | 1.77 [1.16, 2.70] | 0% | Gastrointestinal dysfunction | CRC | 4 | 0.64 [0.36, 1.16] | 0% | No statistical significance | EC | 3 | 0.62 [0.31, 1.22] | 32% | Wang EC [25] | 2 | 0.49 [0.27, 0.90] | 0% | LC | 4 | 0.34[0.13, 0.92] | 65% | Liu et al. LC [16] | 3 | 0.24 [0.09, 0.58] | 45% | Hepatic and renal dysfunction | 7 | 0.79 [0.49, 1.29] | 5% | Wang et al. LC [31] | 5 | 0.54 [0.30, 0.99] | 0% | Zhao et al. LC [29] |
|
|